TRANSVAC2 is the follow-up project to its successful predecessor project TRANSVAC, the European Network of Vaccine Research and Development funded under FP7. The TRANSVAC2 consortium comprises a comprehensive collection of leading European institutions that propose to further advance with the previous initiative to establish a fully operational and sustainable European vaccine infrastructure. TRANSVAC2 supports innovation for prophylactic and therapeutic vaccine development based on a one-health approach, thereby optimizing the knowledge and expertise gained during the development of both human and animal vaccines. This is achieved by bridging the translational gap in biomedical research and supporting cooperation between Europe public institutions and industrial partners. TRANSVAC2 will complement and integrate with existing European research infrastructures in both the public and private sectors. TRANSVAC2 contributes to developing effective products to address European and global health challenges, to controlling the burden and spread of infectious diseases.